Micron Biomedical will be among the select honorees featured in the print edition of Fast Company on newsstands beginning March 31, 2026.

Alongside the rebrand, Terrestrial is planning to establish a new headquarters and manufacturing facility in Boston.

Vaxess Technologies today announced a rebranding to Terrestrial Bio, Inc., along with $50 million in Series C financing.

A recent study on DNA microarray technology highlights its essential role in enabling high-throughput analysis of large numbers of genes through arrays of probes integrated on a solid-phase support.

There are two key things to know about the new Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer from Thermo Fisher Scientific, said Ravi Gupta, vice president and general manager of Thermo ...

Researchers at Cincinnati Children's Hospital Medical Center in collaboration with Roche, have developed a next-generation human liver organoid microarray platform that could help predict which drugs ...

Pimple patches seem to be soaring in popularity—and a newly invented type that makes zits disappear without pain or irrtitation in mere days could soon be all the rage. Researchers have created a ...

SEOUL, South Korea — Acne is one of those frustrating conditions that manages to affect nearly everyone at some point. For some, it’s a passing annoyance of adolescence, while for others, breakouts ...

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s ...